Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Inozyme Pharma, Inc. Common Stock (INZY)

Pharmaceutical Preparations

https://www.inozyme.com

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

321 SUMMER STREET, SUITE 400
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/24/2020

Market Cap

289,205,584

Shares Outstanding

61,760,000

Weighted SO

61,760,748

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

DAWN --.--%

XFOR --.--%

ABOS --.--%

MREO --.--%

TERN --.--%

PDSB --.--%

HOOK --.--%

ELDN --.--%

AMLX --.--%

Beta

1.5230

Last Div

0.0000

Range

2.689-7.795

Chg

-0.0800

Avg Vol

303417

Mkt Cap

289205584

Exch

NASDAQ

Country

US

Phone

857 330 4340

DCF Diff

4.9166

DCF

-0.2316

Div Yield

0.0000

P/S

146.3591

EV Multiple

-3.4707

P/FV

3.0244

Div Yield %

0.0000

P/E

-3.2244

PEG

-0.1550

Payout

0.0000

Current Ratio

9.8425

Quick Ratio

9.8425

Cash Ratio

0.9802

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1275.8722

CCC

-1275.8722

Gross Margin

0.4894

Op Margin

-47.0101

Pretax Margin

-44.8188

Net Margin

-44.8188

Eff Tax Rate

-0.0207

ROA

-0.5688

ROE

-0.6893

ROCE

-0.6627

NI/EBT

1.0000

EBT/EBIT

0.9534

EBIT/Rev

-47.0101

Debt Ratio

0.2973

D/E

0.4903

LT Debt/Cap

0.3244

Total Debt/Cap

0.3290

Int Coverage

-151.5367

CF/Debt

-1.8480

Equity Multi

1.6491

Rec Turnover

0.0000

Pay Turnover

0.2861

Inv Turnover

0.0000

FA Turnover

0.9975

Asset Turnover

0.0127

OCF/Share

-1.3810

FCF/Share

-1.3833

Cash/Share

2.3331

OCF/Sales

-43.2925

FCF/OCF

1.0017

CF Coverage

-1.8480

ST Coverage

-89.2033

CapEx Coverage

-594.0694

Div&CapEx Cov

-594.0694

P/BV

3.0244

P/B

3.0244

P/S

146.3591

P/E

-3.2244

P/FCF

-3.3750

P/OCF

-3.3381

P/CF

-3.3381

PEG

-0.1550

P/S

146.3591

EV Multiple

-3.4707

P/FV

3.0244

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 20, 21:00 Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders GlobeNewswire Inc. May 18, 22:42 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks GlobeNewswire Inc. Nov 09, 08:30 Inozyme Pharma to Participate in Upcoming Investor Conferences GlobeNewswire Inc. Nov 07, 08:30 Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights GlobeNewswire Inc. Nov 03, 16:15 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revenue Product Segmentation